SLC16A3 and cancer: Unlike inhibitors targeting MCT1, other inhibitors, such as AZD3965, are currently undergoing clinical trials for several types of cancers (ClinicalTrials.gov NCT01791595) [36, 37], MCT4 inhibitors remain in the developing phase [10, 38].